| Literature DB >> 32938420 |
Xianrui Chen1,2,3, Shaoqing Guo4,5,6, Dengli Liu1,2,3, Meizhen Zhong1,2,3.
Abstract
BACKGROUND: Raoultella planticola(R.planticola) is a very rare opportunistic pathogen and sometimes even associated with fatal infection in pediatric cases. Recently,the emergence of carbapenem resistance strains are constantly being reported and a growing source of concern for pediatricians. CASEEntities:
Keywords: Case report; Newborn;septicemia; Nosocomial infections; Raoultella planticola
Mesh:
Substances:
Year: 2020 PMID: 32938420 PMCID: PMC7493060 DOI: 10.1186/s12879-020-05409-5
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
General conditions of 4 cases
| Patient | Gender | Gestational age | Birth weight | Maternal illness | Fertilization way | Inpatient days | Delivery way | Twins or multiples | Congenital malformations | The date of isolation of R. planticola |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | male | 211 | 1490 | / | natural pregnancy | 45 | Cesarean delivery | single birth | Patent foramen ovale | 13/06/2019 |
| 2 | male | 253 | 1910 | / | in vitro fertilization | 68 | Cesarean delivery | twins | Patent foramen ovale | 17/06/2019 |
| 3 | female | 215 | 1700 | Gestational diabetes | natural pregnancy | 41 | Transvaginal delivery | single birth | Patent ductus arteriosus | 28/05/2015 |
| 4 | female | 269 | 3000 | / | natural pregnancy | 20 | Transvaginal delivery | single birth | lipoma | 24/05/2015 |
Clinical manifestations in 4 cases
| Patient | Blood culture time (PND) | Nasal feeding time | Mechanical ventilation time | nCPAP | Oxygen time | antibiotics before infection | antibiotics after infection |
|---|---|---|---|---|---|---|---|
| 1 | 26th | 39 | 4 | 25 | 39 | Piperacillin tazobartan sodium (9d + 3d) | Cefepime (14d) |
| Meropenem (7d + 3d) | |||||||
| 2 | 27th | 35 | 7 | 14 | 28 | Piperacillin sodium tazobartan (8d), Cefoperazone/Sulbactam (4d), mepin (9d), vancomycin (4d), cefotaxime sodium (7d) | Cefoperazone/Sulbactam(2d) imipenem (21d) meropenem (14d), amphotericin B(10d) |
| Fluconazole (3d), amphotericin B(18d) | |||||||
| 3 | 20th | 26 | 3 | 5 | 21 | Cefotaxime (14d) | Meropenem (14d), piperacillin tazobartan (7d), benzacillin (7d) fluconazole (10d) |
| Cefoperazone sulbactam (3d) | |||||||
| 4 | 9th | 11 | 6 | 5 | 13 | Piperacillin / Tazobactam (7d) | Meropenem (14d) |
PND Postnatal day, nCPAP Nasal Continuous positive airway pressure,d day
Laboratory test results in 4 cases
| Patient | WBC (10^9/L) | NE% | CRP (mg/L) | HGB (g/L) | PLT (10^9/L) | PCT (ng/mL) | G test | Number of positive blood culture | Other bacterial infections |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 18.06 | 89.7 | 13.54 | 123 | 146 | 15.13 | negative | 1 | / |
| 2 | 22.23 | 74 | 110.16 | 116 | 65 | 12.90 | negative | 3 | Candida gigas, |
| 3 | 1.89 | 16.90 | 8 | 101 | 125 | / | negative | 1 | / |
| 4 | 52.51 | 89.40 | 76 | 124 | 532 | 13.8 | negative | 1 | / |
WBC White blood cell count, CRP C-reactive protein, NE% neutrophil percentage, HGB Hemoglobin, PLT Blood platelet count, PCT Procaicltonin, G test (1,3) beta-D-glucan assay
Antimicrobial susceptibility
| antibiotics | Patient 1 | Patient 2 | Patient 3 | Patient 4 | ||||
|---|---|---|---|---|---|---|---|---|
| antibiotic susceptibility | MIC | antibiotic susceptibility | MIC | antibiotic susceptibility | MIC | antibiotic susceptibility | MIC | |
| Amikacin | S | <=2.0 | S | <=2.0 | S | <=2.0 | S | <=2.0 |
| Ampicillin-sulbactam | R | > = 32.0 | R | > = 32.0 | R | > = 32.0 | R | > = 32.0 |
| Aztreonam | R | 16 | R | 16 | R | 16 | R | 16 |
| Cefazolin | R | > = 64.0 | R | > = 64.0 | R | > = 64.0 | R | > = 64.0 |
| Cefepime | S | 2 | S | 2 | R | 16 | R | 16 |
| Cefotetan | R | > = 64.0 | R | > = 64.0 | R | > = 64.0 | R | > = 64.0 |
| Ceftazidime | R | > = 64.0 | R | > = 64.0 | R | > = 64.0 | R | > = 64.0 |
| Ceftriaxone | R | > = 64.0 | R | 32 | R | > = 64.0 | R | > = 64.0 |
| Cefuroxime | R | > = 64.0 | R | > = 64.0 | R | > = 64.0 | R | > = 64.0 |
| Cefuroxime Axetil | R | > = 64.0 | R | > = 64.0 | R | > = 64.0 | R | > = 64.0 |
| Ciprofloxacin | R | 1 | R | 1 | S | <=0.25 | S | <=0.25 |
| Gentamicin | R | > = 16.0 | R | > = 16.0 | S | <=1 | S | <=1.0 |
| Levofloxacin | R | 4 | I | 1 | S | <=0.25 | S | <=0.25 |
| Piperacillin | R | > = 128.0 | R | > = 128.0 | R | > = 128.0 | R | > = 128.0 |
| Piperacillin/Tazobactam | I | 32 | S | 16 | I | 64 | I | 64 |
| Tobramycin | R | > = 16.0 | I | 8 | S | 4 | S | 4 |
| Trimethoprim/sulfamethoxazole | S | <=20.0 | S | <=20.0 | S | <=20 | R | > = 320 |
| Imipenem | R | > = 16.0 | R | 8 | R | 8 | R | 4 |
| Meropenem | I | > = 16.0 | R | > = 16.0 | S | 4 | S | 4 |
MIC Minimum inhibitory concentration, S Sensitive, R Resistance, I Intermediary